No Interaction Expected
Quality of Evidence:
No clinically significant interaction was observed when delamanid and tenofovir-DF were coadministered. Coadministration of delamanid (100 mg twice daily) and tenofovir-DF (300 mg once daily) did not affect delamanid Cmax (16% decrease) or AUC (4% decrease). Tenofovir exposure was unchanged (11% decrease in Cmax, 9% decrease in AUC; n=13).
Coadministration of delamanid (100 mg twice daily) and tenofovir-DF (300 mg once daily) was studied in 13 HIV and TB uninfected subjects. Delamanid Cmax and AUC decreased by 16% and 4%; tenofovir Cmax and AUC decreased by 11% and 9%. The small changes seen are not clinically relevant and are in agreement with the expectation of a lack of interaction based on the metabolic profile of tenofovir and delamanid.
Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Mallikaarjun S, Wells C, Petersen C, et al. Antimicrob Agents Chemother, 2016, 60(10): 5976-85.
View all available interactions with
Tenofovir-DF (TDF) by clicking